Arvinas LLC(ARVN) - 2023 Q4 - Annual Results

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study leadin for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include ...